A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia

Critical Care

Volumn 16, Issue 6, 2012, Pages

  Kollef, Marin H ^a   Chastre, Jean ^b   Clavel, Marc ^c   Restrepo, Marcos I ^d   Michiels, Bart ^e   Kaniga, Koné ^f   Cirillo, Iolanda ^f   Kimko, Holly ^f   Redman, Rebecca ^f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CILASTATIN PLUS IMIPENEM; DORIPENEM; LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CILASTATIN; IMIPENEM;

ACINETOBACTER; ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DECUBITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTERIACEAE; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; HYPOKALEMIA; HYPOTENSION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; ADOLESCENT; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CILASTATIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIPENEM; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; YOUNG ADULT;

EID: 84868667406     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11862     Document Type: Article

References (34)

1. Kollef MH. Ventilator-associated pneumonia. A multivariate analysis. JAMA 1993, 270:1965-1970. 10.1001/jama.1993.03510160083034, 8411554.
2. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, . EPIC II Group of Investigators International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329. 10.1001/jama.2009.1754, 19952319, EPIC II Group of Investigators.
3. American Thoracic Society Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. American Thoracic Society Infectious Diseases Society of America.
4. Rotstein C, Evans G, Born A, Grossman R, Light RB, Magder S, McTaggart B, Weiss K, Zhanel GG. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol 2008, 19:19-53. 2610276, 19145262.
5. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, . PneumA Trial Group Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated, pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598. 10.1001/jama.290.19.2588, 14625336, PneumA Trial Group.
6. Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2011, 10:CD007577.
7. Fink MP, Snydman DR, Niederman MS, Leeper KV, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994, 38:547-557. 10.1128/AAC.38.3.547, 284496, 8203853.
8. Réa-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, Ketter N, Prokocimer P, Friedland I. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008, 24:2113-2126. 10.1185/03007990802179255, 18549664.
9. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008, 36:1089-1096. 10.1097/CCM.0b013e3181691b99, 18379232.
10. Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 2009, 63:409-414. 10.1016/j.diagmicrobio.2009.01.027, 19249182.
11. Vaccaro N, Umeh O, Redman R, Cirillo I. Pharmacokinetics of doripenem 1 g administered over 4 hours in patients with ventilator-associated pneumonia. Proceedings of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009, 12-15. San Francisco, California, [Abstract: A1-018].
12. Drusano GL, Lodise TP, Melnick D, Liu W, Oliver A, Mena A, VanScoy B, Louie A. Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets. Antimicrob Agents Chemother 2011, 55:3406-3412. 10.1128/AAC.01559-10, 3122433, 21576431.
13. Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 2011, 37:632-638. 10.1007/s00134-010-2105-0, 21136037.
14. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001, 29:1109-1115. 10.1097/00003246-200106000-00003, 11395584.
15. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004, 125:1791-1799. 10.1378/chest.125.5.1791, 15136392.
16. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162:505-511.
17. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M, . PRORATA trial group Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474. 10.1016/S0140-6736(09)61879-1, 20097417, PRORATA trial group.
18. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009, 34:1364-1375. 10.1183/09031936.00053209, 19797133.
19. Hedrick TL, McElearney ST, Smith RL, Evans HL, Pruett TL, Sawyer RG. Duration of antibiotic therapy for ventilator-associated pneumonia caused by non-fermentative gram-negative bacilli. Surg Infect 2007, 8:589-597.
20. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008, 134:281-287. 10.1378/chest.08-1116, 18682456.
21. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012, 54:670-680. 10.1093/cid/cir934, 22322268.
22. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, Chuang YC, Maroko RT, Dukart G, Cooper CA, Korth-Bradley JM, Dartois N, Gandjini H, . 311 Study Group Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010, 68:140-151. 10.1016/j.diagmicrobio.2010.05.012, 20846586, 311 Study Group.
23. Neuner E, Ritchie D, Micek S. New antibiotics for healthcare associated pneumonia. Semin Respir Crit Care Med 2009, 30:92-101. 10.1055/s-0028-1119813, 19199191.
24. Basilea announces positive top-line data from phase III study of ceftobiprole in hospital-acquired pneumonia. [press release] October 9, 2007. Accessed October 10, 2011, at., http://www.basilea.com/News-and-Media/Basilea-Announces-Positive-Top-line-Data-from-Phase-III-Study-of-Ceftobiprole-in-Hospital-Acquired-Pneumonia/144
25. Tamma PD, Putcha N, Suh YD, Van Arendonk KJ, Rinke ML. Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infect Dis 2011, 11:181. 10.1186/1471-2334-11-181, 3141415, 21696619.
26. Roberts J, Webb S, Paterson D, Ho K, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009, 37:2071-2078. 10.1097/CCM.0b013e3181a0054d, 19384201.
27. Justo J, Gotfried MH, Deyo K, Fischer P, Danziger LH, Rodvold KA. Doripenem intrapulmonary pharmacokinetics in healthy adult subjects. Proceedings of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 2011, Chicago, Illinois [Abstract: A1-1748].
28. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64:142-150. 10.1093/jac/dkp139, 19398460.
29. Bulitta JB, Landersdorfer CB, Forrest A, Brown SV, Neely MN, Tsuji BT, Louie A. Relevance of pharmacokinetic and pharmacodynamic modelling to clinical care of critically ill patients. Curr Pharm Biotechnol 2011, 12:2044-2061. 10.2174/138920111798808428, 21554212.
30. Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients- a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011, 15:R206. 10.1186/cc10441, 3334750, 21914174.
31. Udy A, Roberts J, Lipman J. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol 2011, 7:539-543.
32. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney B, Ungerer J, Lipman J, Roberts JA. Subtherapeutc initial β-lactam concentrations in select critically ill patients. Association between augmented renal clearance and low trough drug concentrations. Chest 2012, 142:30-39. 10.1378/chest.11-1671, 22194591.
33. Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, So TM, Yasin RM, Hsueh PR, Carlos CC, Hsu LY, Buntaran L, Lalitha MK, Kim MJ, Choi JY, Kim SI, Ko KS, Kang CI, Peck KR, . Asian Network for Surveillance of Resistant Pathogens Study Group High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011, 184:1409-1417. 10.1164/rccm.201102-0349OC, 21920919, Asian Network for Surveillance of Resistant Pathogens Study Group.
34. European Medicines Agency: Science Medicines Health European Medicines Agency: Science Medicines Health., http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2012/06/human_pha_detail_000064.jsp&mid=&source=homeMedSearch&category=human